Cancer/Tumor Profiling Market | Ongoing Trends and Recent Developments | Major Key Players like Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US)

The Growth in Cancer/Tumor Profiling Market is driven by the increasing incidences of cancer across the globe and the growing use of biomarkers in tumor profiling. Also, the increase in cancer research & funding initiatives and technological advancements in profiling technologies are propelling market growth.

What the Market Looks Like?

Predicted to grow at a CAGR of 10.5% during the forecast period, the Global Cancer/Tumor Profiling Market is estimated to reach USD 12.4 billion by the end of 2024. The APAC market is expected to grow at the highest CAGR during the forecast period

Based on technology, Cancer/Tumor Profiling Market has been segmented into immunoassays, in-situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share in 2018. This can be attributed to the fact that these assays are used as a gold standard to conduct tumor profiling on a large scale as they help measure the presence and concentration of analytes in a sample. These tests are used for cancer diagnosis, prognosis, and treatment decisions.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1250

Based on cancer type, Cancer/Tumor Profiling Market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. In 2018, the breast cancer segment accounted for the largest share of Cancer/Tumor Profiling Market. The high prevalence of breast cancer across the globe is the primary factor contributing to the large share of this segment. Cancer requires the use of different profiling techniques for early diagnosis and screening.

Based on biomarker type, the market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers. In 2018, genetic biomarkers accounted for the largest share of Cancer Profiling Market. The large share of this segment can be attributed to the high adoption of these biomarkers during cancer diagnosis & prognosis and in the biomarker discovery process.

What Drives the Cancer/Tumor Profiling Market?

The growth of the global market for Cancer/Tumor Profiling is primarily influenced by the following factors:

• Increasing Incidence of Cancer
• Increasing Use of Biomarkers in Cancer Profiling
• Increasing Cancer Research and Funding
• Technological Advancements

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1250

Geographical growth scenario of Cancer/Tumor Profiling Market:

In 2018, North America dominated global market, followed by Europe. Increasing investments for the discovery & development of biomarkers, growing demand for personalized therapeutics, rising adoption of advanced omics technologies for cancer research, and the increasing use of biomarkers for drug development with regard to the rising incidences of cancer are the factors propelling the growth of the market in the region. The presence of a large number of global players in this region is another key factor contributing to the large share of this market segment.

Leading market players and strategies adopted:

Prominent players in Cancer/Tumor Profiling Market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), RiboMed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).

Read More in Detailed: https://www.marketsandmarkets.com/PressReleases/cancer-tumor-profiling.asp

Contact Us:

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.